OTC:NVGNF

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...

2019-12-11 08:41 6487

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and ...

2019-09-13 20:00 7578

St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's in...

2019-09-12 21:10 7641

Australian cancer specialists may hold key to next advancement in ovarian cancer treatment

SYDNEY, Aug. 30, 2017 /PRNewswire/ -- Three leading Australian cancer treatment centres are at the forefront of a drug trial that could see the next major advancement in ovarian cancer therapy. Associate Professor Jim Coward, an oncologist at Icon Cancer Care in South Brisbane, is leading the fi...

2017-08-31 06:00 3777

GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

SYDNEY, Aug. 22, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage drug development candidate, GDC-0084. GDC-0084 was in-licensed from Genentech, Inc inOcto...

2017-08-22 12:06 3393

Progress Update on Cantrixil(TM) (TRXE-002-1) Development

SYDNEY, Aug. 7, 2017 /PRNewswire/ -- Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology drug development company, is pleased to provide an update to investors on progress with its clinical-stage development candidate, Cantrixil (TRXE-002-1). Phase I Clinical Trial in Ovarian Cancer Pro...

2017-08-07 11:03 3810

Novogen Provides Update On Development Of Cantrixil

SYDNEY, May 2, 2016 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian canc...

2016-05-02 10:43 3861

Studies Confirm TRXE-009 Crosses the Blood-brain Barrier

NEW YORK, June 5, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue. This confirms that the d...

2015-06-05 07:30 3277

Australian Studies Confirm TRXE-009 Kills Resistant Paediatric Brain Cancer Cells

SYDNEY and SAN DIEGO, May 8, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), in conjunction with Australian paediatric cancer researchers, released key pre-clinical data on experimental cancer drug-candidate, TRXE-009, confirming its potential to...

2015-05-08 06:54 3278

Australian Studies Confirm Anisina as Potential Important New Weapon Against Melanoma

SYDNEY, April 9, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen (NRT:ASX; NVGN: NASDAQ), today announced that studies conducted at The University of Queensland Diamantina Institute (UQDI) revealed that experimental drug, Anisina, killed melanoma cells irrespective of their muta...

2015-04-09 11:06 2617

Potential of Anisina to Become Major New Chemotherapy Confirmed by Coda Study

SYDNEY, March 19, 2015 /PRNewswire/ -- Novogen announced on 18th March, 2015 that one of its oncology pipeline drug candidates, Anisina (ATM-3507), has achieved a major milestone in its development, confirming the concept that comprehensive destruction of a cancer cell's cytoskeleton can deliver ...

2015-03-19 04:00 3419

Sky News, Helen Dalley interviews Dr Graham Kelly

SYDNEY, March 10, 2015 /PRNewswire/ -- Novogen Ltd (ASX: 'NRT'; Nasdaq: 'NVGN')CEO, Dr Graham Kelly, PhD, was interviewed by Sky News', Helen Dalley about the breakthrough brain cancer drug being developed by Novogen. Novogen is an Australian-US drug discovery company focused on the clinical ...

2015-03-10 12:28 2709

Week's Top Stories